Lisata Therapeutics, Inc. (LSTA) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $14.9M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLisata Therapeutics, Inc. (LSTA) trades at $1.64 with MoonshotScore 18/100 (Grade F). Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cellular therapies.
Price as of Sep 10, 2026 · Last analyzed: Sep 10, 2026Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cellular therapies. Their product candidates include HONEDRA, XOWNA, and CLBS201, targeting critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease, respectively.
LSTA stock analysis for 2026: The stored analyst price target for Lisata Therapeutics, Inc. is $9.50; its date is unknown, so no upside or downside is derived from it against the current price of $1.64. The AI MoonshotScore is 18/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
LSTA: 2/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Strongest side: Growth Durability (5/10, Neutral). Weakest side: Valuation (0/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Lisata Therapeutics, Inc. Company Overview
Who Are LSTA's Competitors?
LSTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | — |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | — |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | — |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for LSTA?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 94% of our measures
- ● Price is current
- ● Latest filing 183 days ago
- ● Covered by analysts
Why 18?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.28 Gross margin (Business Quality)
- +0.14 Debt to equity (Financial Strength)
- +0.11 5-year net income per share (Growth)
What is holding it back
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
- -0.78 Free cash flow yield (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 17 |
| 2026-08-26 | 17 |
| 2026-08-29 | 17 |
| 2026-09-01 | 18 |
| 2026-09-04 | 18 |
| 2026-09-07 | 18 |
| 2026-09-10 | 18 |
What changed?
The grade moved from 17 to 18 (+1).
What moved it up or down:
- +5 Momentum
- +2 Business Quality
- +2 Growth
Over the same 18 days the stock moved +22.6%.
LSTA Valuation & Market Position
With a $14.9M market cap, Lisata Therapeutics, Inc. sits in the micro-cap segment of the market.
Earnings Track Record
Lisata Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.0% above estimates on average.
Financial Health
Lisata Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Its free cash flow yield is -67.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -81.1%, the inverse of the P/E and a quick read on earnings relative to price.
Forward Outlook
Wall Street analysts project Lisata Therapeutics, Inc. revenue of about $135K for fiscal 2026, with EPS near $-1.09.
Insider Activity
The most recent 12 insider filings for Lisata Therapeutics, Inc. break down as 8 sales and 4 purchases. On net that is roughly 96K shares acquired (about $544) — insiders putting money in tends to read as conviction.
LSTA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $100,000 | -$3M | -$0.33 |
Q4 FY2025 · filed 12 Mar 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
LSTA Latest News
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Aug 21, 2026
-
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
proactiveinvestors.com · Aug 5, 2026
-
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
benzinga · Aug 4, 2026
-
Lisata Therapeutics moves forward with legal action following Kuva merger termination
proactiveinvestors.com · Aug 4, 2026
LSTA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LSTA.
Price Targets
Consensus target: $9.50
LSTA MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. LSTA scores 18/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
12 Health Care Stocks Moving In Friday's Intraday Session
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Latest Lisata Therapeutics, Inc. Analysis
Common Questions About LSTA
What does the AI Score mean for LSTA?
LSTA holds an AI Score of 18/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is LSTA a good stock?
Stock Expert AI does not rate LSTA buy, sell or hold. Lisata Therapeutics, Inc. carries a MoonshotScore of 18/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for LSTA?
Lisata Therapeutics, Inc. (LSTA) holds an AI score of 18/100 (low). Not financial advice.
How frequently does LSTA data refresh on this page?
LSTA's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LSTA's recent stock price performance?
Lisata Therapeutics, Inc. (LSTA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LSTA overvalued or undervalued right now?
Lisata Therapeutics, Inc. (LSTA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of LSTA?
Yes, most major brokerages offer fractional shares of Lisata Therapeutics, Inc. (LSTA) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track LSTA's earnings and financial reports?
Lisata Therapeutics, Inc. (LSTA) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for LSTA earnings announcements.
What should investors new to LSTA understand first?
Lisata Therapeutics, Inc. (LSTA) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 18/100. With a market cap of $14.9M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.